Global Initiative of Nestor Pharmaceuticals Ltd Receives MHRA

New Delhi, Delhi, India

Nestor UK Ltd, a part of Nestor pharmaceuticals Ltd, one of India's leading pharmaceutical companies has acquired MHRA which will enable Nestor's foray into supply of medicines to the regulated market of European region. Nestor UK took over the full facility of US pharmaceutical giant Schering - Plough at Mildenhall Suffolk in the UK in the year 2006. Nestor has invested nearly £10 million in renovating the plant to make it one of the advance plants of UK.

With receiving of MHRA, Nestor UK Ltd becomes one of the first Indian pharmaceutical companies in India that had invested in a facility in UK, revamped and upgraded the site to be able to meet required standards to further apply for MHRA. Nestor projects the annual capacity of the plant to produce over 1 billion tablets, 500 tons of semi solids and 15 million beta lactum (API) capsules.

Explaining about the future plans of first global initiative of the organization, Mr. Rahul Sehgal, President - Nestor pharmaceuticals Ltd said," By acquiring the plant previously owned by Schering - Plough, Nestor has been able to create additional capacity in tablets, semi solids and Beta Lactums presently. In future, we would like to add capacity for manufacturing syrups, dry powders, and non beta lactums to augment the plant's full capacity. We also have plans to further expand into the neighboring European markets like Germany and France in the first stage of our expansion in this region. Our first year projections are set as £10 million and aim is to register a 40 percent growth y-o-y. We also plan to establish leads in Beta Lactum and semi solids (ointments and creams) manufacturing. Nestor also envisions producing controlled substance pharmaceutical formulations for the UK market so as put the plant to its optimum and best use."

The new base for Nestor, Mildenhall had witnessed a long tradition of pharmaceutical manufacturing. Its central location with proximity to ports, roadwork and knowledge centers like University of East Anglia's medical and pharmaceutical college in Norwich made it an ideal choice for Nestor. The eight acre facility rechristened as Nestor UK Ltd went on stream in February 2008 and is also amongst the largest for storing controlled drugs. Nestor UK is set to impact Europe through channel partnerships with branded drug-store chains. Nestor products will soon be visible on European shelves.

Nestor has also spread itself to other parts of the world where the requirements of medicines is acute. Nostrum Pharmaceuticals, a wholly owned subsidiary of Nestor was set up in Africa in the year 2005 to be able to meet the large volumes demand of low-cost yet quality drugs. It has since then made a substantial difference to public health through its technology-driven facility in Lagos. Sixteen channel partners have set up a distribution network to reach 130 million Nigerians. Nostrum is set to replicate its Nigerian experience across Central, North and East Africa by end of year 2009.

Note to Editor

About Nestor Pharmaceuticals:

Nestor is headquartered at New Delhi and has three plants in India - formulation plants at Haryana (Faridabad) and Goa, bulk drug (API) plant in Andhra Pradesh (Hyderabad) and two other plants in the UK and Nigeria. Nestor is one of the leading pharmaceutical companies in India manufacturing a wide range of essential medicines: over 150 different formulations including standard generic tablets, capsules, liquids, injections, ointments and dry syrups. Around 70% of all prescriptions across the world feature the type of formulations that Nestor makes. Nestor is India's upcoming leading producer of Beta Lactum (API).Nestor provides medicines for almost all categories - anti tuberculosis, anti malaria, anti retroviral (HIV), orthopedic segment, broad spectrum antibiotics, cardiac and diabetic, neurology and dermatology. Nestor is ISO - 9001 / 14001 accredited and WHO - GMP certified. Nestor's well developed packaging and product development department ensures manufacturing procedures are constantly updated to produce products with improved bioavailability.

About MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency of UK which is responsible for ensuring that medicines and medical devices work, and are acceptably safe. It works towards ensuring that the benefits of products reaching to patients and the public justify the risks. MHRA enables greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public. It encourages public, healthcare professionals and industry bodies discuss problems associated with a medicine or medical device, investigate and take any necessary action.

Source: Nestor Pharmaceuticals (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.